BioMed Research International / 2019 / Article / Tab 1

Research Article

Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study

Table 1

Baseline demographic and clinical characteristics of the patients (n=498).

CharacteristicTACE+sorafenib  
(n=69)
TACE  
(n=429)
X2/t/z  
Value
P Value

Age51 (21-79)51 (18-84)-0.4310.667
Sex
 Male593800.5370.464
 Female1049
Child-Pugh
 A674060.7560.385
 B223
AFP12307.24±20255.8819716.23±25103.12-2.1170.034
Number
 <35836800.985
 ≥31168
Size8.39±4.459.65±3.25-2.0200.043
Type
 I/II431829.4990.002
 III/IV26247
Treatment after TACE
 surgery150.0140.993
 RFA16
 radiotherapy211

p<0.05

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.